title: Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
abstract: BACKGROUND
  To determine the changes in plasma lipid levels in symptomatic benign prostatic hyperplasia (BPH) patients receiving terazosin treatment.
  
  
  METHODS
  The study included 99 patients with BPH aged 44-74 years. The patients were divided into 3 groups: in group 1 (n = 25) with baseline total cholesterol levels of >220 mg/dl, terazosin 5 mg/day was used; in group 2 (n = 56) with basal total cholesterol levels of < 220 mg/dl, terazosin 5 mg/day was used, and group 3 (n = 18) did not use terazosin and was defined as the control group. Plasma levels of total cholesterol, low-density lipoprotein, high-density lipoprotein and triglyceride were recorded, and the high-density lipoprotein to total cholesterol ratio was calculated at the beginning of the study and after 12 weeks.
  
  
  RESULTS
  The total cholesterol level decreased from the baseline level by 10.88% after 12 weeks (p < 0.05) in group 1. The decrease was observed in 22 of 25 patients (88%). In group 1, the mean plasma total cholesterol level decreased significantly (p < 0.05), but the decrease was not significant in group 2 and no change was observed in group 3. The mean plasma low-density lipoprotein level decreased significantly in group 1 (p < 0.05), but no change was observed in the other 2 groups. The mean plasma high-density lipoprotein level increased in group 1, whereas no change was observed in the other 2 groups. The mean plasma triglyceride level decreased significantly in groups 1 and 2 (p < 0.05), but no change was observed in group 3. The high-density lipoprotein to total cholesterol ratio increased significantly in group 1, but no change was observed in the other 2 groups.
  
  
  CONCLUSIONS
  We suggest that terazosin may be a reasonable choice because of the beneficial effect on the lipid profile in older symptomatic BPH patients with a higher ratio of dyslipidemia.
authors.affiliation: Department of Urology, University of Mersin, Turkey. erakbay@mersin.edu.tr
authors.forename: E
authors.initials: E
authors.lastname: Akbay
authors.forename: M
authors.initials: M
authors.lastname: Bozlu
authors.forename: E
authors.initials: E
authors.lastname: Doruk
authors.forename: E
authors.initials: E
authors.lastname: Akbay
authors.forename: S
authors.initials: S
authors.lastname: Cayan
authors.forename: E
authors.initials: E
authors.lastname: Ulusoy
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood*; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000494:pharmacology*; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D014280:Triglycerides / Q000097:blood*
chemical_list: D000317:Adrenergic alpha-Antagonists; D008074:Lipoproteins; D014280:Triglycerides; C041226:Terazosin; D002784:Cholesterol; D011224:Prazosin